-
Universal barcodes unlock fast-paced small molecule synthesis
12/11/2024
Learn how St. Jude scientists discovered a universal barcode in fragmentation patterns to revolutionize chemical reaction analysis and small molecule synthesis.
-
St. Jude names Maria Megdal as executive vice president and chief administrative officer
12/10/2024
Medgal will oversee departments vital to St. Jude operations. She previously led operations at major cancer centers in Boston and New York
-
Research links a genetic risk for schizophrenia to a malformed skull
12/05/2024
See how St. Jude scientists study 22q schizophrenia disorder finding flocculus and paraflocculus growth in cerebellum curbed by lack of skull growth gene Tbx1
-
Predicting cardiac issues in cancer survivors using a serum protein panel test
12/03/2024
See how a blood serum panel of 27 proteins can accurately predict anthracycline-related cardiomyopathy risk in subclinical pediatric cancer survivors
-
St. Jude appoints leading scientist to create groundbreaking Center of Excellence for Structural Cell Biology
11/21/2024
Georgios Skiniotis, PhD, to develop and lead new center focusing on advanced imaging techniques, including cryo-ET.
-
Scientists from St. Jude Children’s Research Hospital listed among most cited globally
11/19/2024
Meet the St. Jude scientists named to the 2024 list of Highly Cited Researchers produced by Clarivate, to celebrate the global influence of their discoveries.
-
St. Jude researchers identify unexpected genetic link between skin disorder and inner ear
11/18/2024
Discover St. Jude research showing how the ABC transporter links inner ear development with hearing impairment in dyschromatosis universalis hereditaria.
-
Glutamine metabolic switch is key to red blood cell development and disease
11/14/2024
See how a switch from glutamine catabolism to glutamine production is a vital step in blood cell development linking the process to sickle cell disease and β-thalassemia
-
Tumor suppressor forms gel-like assemblies to sacrifice cancer cells
11/11/2024
See how the tumor suppressor p14ARF undergoes phase separation with nucleophosmin to form condensates which arrest ribosome formation to kill cancer cells.
-
Mitchell Weiss of St. Jude Children’s Research Hospital elected to the National Academy of Medicine
10/23/2024
Leading expert in catastrophic blood disorders becomes the seventh St. Jude faculty member tapped for this honor
-
Nutrients and organelle signaling shape tissue immunity
10/14/2024
Discover research by Hongbo Chi, PhD, that uncovers the interplay between organelles, nutrient-dependent signaling pathways and tissue immunity.
-
Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy
10/10/2024
Explore how disruptions in ASXL1 were correlated with better patient responses to immune checkpoint inhibition and long-term tumor control in model systems.
-
St. Jude ranks in top 10 of U.S. News Best Children's Hospitals for Cancer
10/08/2024
US News & World Report has recognized St. Jude Children's Research Hospital as one of the top 10 pediatric cancer hospitals for the 17th straight year.
-
St. Jude names M. Madan Babu, PhD, senior vice president and chief data scientist
10/01/2024
M. Madan Babu, PhD, will lead new $195 million data science enterprise for biologic discovery to advance pediatric medicine.
-
Structure of a eukaryotic CRISPR-Cas homolog, Fanzor2, shows its promise for gene editing
10/01/2024
See how structures of Fanzor2, a relation of the transposon family TnpB, show how the protein can be used in genome engineering technology like CRISPR-Cas9.
-
Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes
09/24/2024
Learn about St. Jude clinical trial findings from Hiroto Inaba, MD, PhD, showing that genomics can guide risk assessment and leukemia treatment intensity.
-
Urate transporter structures reveal the mechanism behind important drug target for gout
09/09/2024
Discover how cryo-EM insights into URAT1, a urate transporter and member of the SLC22 transporter family advance gout and hypouricemia drug discovery
-
Early interventions may improve long-term academic achievement in young childhood brain tumor survivors
08/21/2024
Find how children who survive a brain tumor often fall behind peers in academic readiness, but access to early developmental resources may reduce the gap.
-
T helper cells may be the key to improving annual influenza vaccines
08/20/2024
Explore how T follicular helper cells indirectly control the anti-influenza immune response, which could lead to improvements in annual flu vaccine design.
-
First successful treatment of pediatric high-risk refractory neuroblastoma with PARP inhibition
08/14/2024
Explore the first successful treatment of a pediatric patient with high-risk refractory neuroblastoma using PARP inhibition guided by clinical genomics.
-
New research from Children’s Hospital of Philadelphia and St. Jude poised to transform approach to diagnosing and treating acute leukemia in children
08/14/2024
Explore How research St. Jude and CHOP is transforming Acute Leukemia Diagnosis and Treatment in Children.
-
Study reveals oleoyl-ACP-hydrolase underpins lethal respiratory viral disease
08/12/2024
Learn how research from St. Jude, Doherty Institute and others revealed that OLAH underpins deadly respiratory disease from viruses such as RSV and Sars-Cov-2.
-
Scientists identify genes linked to relapse in the most common form of childhood leukemia
08/09/2024
Discover St. Jude research from Charles Mullighan, MD, identifying novel genetic alterations linked to relapse in standard risk acute lymphoblastic leukemia.
-
St. Jude identifies SARS-CoV-2 “mimic” contributing to pediatric inflammatory syndrome
08/07/2024
Discover St. Jude research from Paul Thomas, PhD, linking SARS-CoV-2 infections and molecular mimicry with multisystem inflammatory syndrome in children.
-
Genetic ‘episignatures’ guide researchers in identifying causes of unsolved epileptic neurological disorders
08/06/2024
See how DNA methylation patterns can be used to identify and diagnose rare neurogenetic disorder cases of developmental and epileptic encephalopathies
-
Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia
08/05/2024
Explore how scientists at St. Jude Children’s Research Hospital have identified causes for age-related differences in the treatment outcomes of B-cell acute lymphoblastic leukemia.
-
Improved chemokine homing enhances CAR T-cell therapy for osteosarcoma
08/05/2024
Learn how scientists at St. Jude are leading research to improve CAR T-cell therapy for osteosarcoma by enhancing chemokine homing.
-
Serotonin uptake regulates ependymoma tumor growth
07/31/2024
Discover how St. Jude Children’s Research Hospital and Baylor College of Medicine found serotonin's role in ependymoma tumor growth, opening new drug possibilities.
-
St. Jude gene panel for pediatric cancers increases access to high-quality testing
07/26/2024
Discover how a gene panel for pediatric cancer concentrates the pediatric cancer genome project & high-end sequencing’s findings into a single practical test.
-
St. Jude Children’s Research Hospital earns DNV accreditation
07/23/2024
Collaboration between St. Jude and DNV will strengthen the institution’s processes and improve patient care.
-
Lab-grown human neuron assembloids effectively model synaptic plasticity
07/18/2024
See how St. Jude scientists model the human thalamocortical neural network using lab-grown cells, revealing synaptic communication and demonstrating plasticity.
-
Biomolecular condensate ‘molecular putty’ properties found encoded in protein sequence
07/02/2024
See how biomolecular condensates like stress granules behave like putty, a viscoelastic material that shares properties of liquids and solids based on the timescale of interactions.
-
Master autoimmune regulator gets by with a little help from its friends
06/27/2024
See how St. Jude researchers investigated Foxp3 function as a transcription cofactor in regulatory T cells in immune system activation and suppression.
-
Study identifies high-risk type of childhood acute leukemia and potential treatment strategy
06/25/2024
Learn how St. Jude assembled an international cohort to better understand γδ T-ALL, a high-risk form of childhood cancer, and propose a new targeted treatment.
-
Children genetically prone to cancer benefit from early standardized surveillance
06/20/2024
Discover new research that shows cancer surveillance deployed immediately after finding a genetic predisposition leads to earlier tumor detection & treatment.
-
St. Jude scientists solve decades long mystery of NLRC5 sensor function in cell death and disease
06/14/2024
Learn about immunology research from the St. Jude laboratory of Thirumala-Devi Kanneganti, PhD, that revealed the function of the NLRC5 innate immune sensor.
-
Novel insights into fluorescent ‘dark states’ illuminate ways forward for improved imaging
06/14/2024
See how fluorescent dark triplet states in single molecule FRET can be avoided with self-healing fluorophores.
-
Age is just a number: Immune cell ‘epigenetic clock’ ticks independently of organism lifespan
06/12/2024
See how St. Jude researchers use epigenetic clock, DNA methylation and mouse model to demonstrate that T cell proliferation can stretch past organism lifespan and acute lymphoblastic leukemia T cells appear hundreds of years old.
-
‘Goldilocks’ binding strength determines anti-cancer T-cell efficacy and fate
05/30/2024
Learn how progenitor exhausted T cells’ receptor binding strength to cancer antigens determines the anti-cancer response with implications for immunotherapy.
-
Cell-targeting technology allows researchers to isolate neuronal subpopulations and link them to behavioral states
05/27/2024
See how neurology tool Conditional Viral Expression by Ribozyme Guided Degradation (ConVERGD) allows researchers to isolate subpopulations of cells with increased accuracy and ease
-
Repurposed protease controls important signaling molecule-activating protein
05/22/2024
See how cryo-EM reveals iRhom2 acts as regulator of ADAM17 activity and controls activation of tumor necrosis factor and many growth factors by binding ADAM17 prodomain.
-
Novel inhibitor insights offer pathway to preventing PXR-associated drug resistance
05/14/2024
See how novel pregnane X receptor inhibitors offer structural understanding behind activator and repressor activity, guiding future drug design research to combat drug resistance
-
Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targets
05/03/2024
St. Jude found 156 potential targets for chimeric antigen receptor (CAR) T–cell immunotherapy. Explore the discovery’s promise to improve cancer therapies.
-
Unraveling the roles of non-coding DNA explains childhood cancer’s resistance to chemotherapy
05/01/2024
Non-coding DNA variants contribute to acute lymphoblastic leukemia (ALL) chemotherapy resistance. Explore new technology used in the St. Jude-led discovery.
-
Hongbo Chi, PhD named 2023 AAAS Fellow
04/29/2024
The St. Jude immunologist has made valuable contributions to immunometabolism. AAAS is the world’s largest general scientific society.
-
Targeting specific protein regions offers a new treatment approach in medulloblastoma
04/25/2024
Explore how research targeting EP300/CBP protein in Group 3 medulloblastoma may advance targeted pediatric brain tumor treatments by inhibiting bromodomains.
-
Genetics predict type 2 diabetes risk and disparities in childhood cancer survivors
04/23/2024
Learn how ancestry changes genetic risk variants’ impact on type 2 diabetes in childhood cancer survivors & alkylating agent exposure magnifies diabetes risk.
-
Metabolic health before vaccination determines effectiveness of anti-flu response
04/18/2024
Poor metabolic health or dysfunction, not obesity, leads to poor anti-influenza immune responses. Learn about the new St. Jude influenza vaccination research.
-
Andrew Smith, MD, PhD, named chair of Diagnostic Imaging at St. Jude Children’s Research Hospital
04/15/2024
Andrew Smith, MD, PhD, named chair of Diagnostic Imaging at St. Jude Children's Research Hospital. Smith is an expert in the use of artificial intelligence in imaging and medicine.
-
New drug prevents flu-related inflammation and lung damage
04/10/2024
New RIPK3 inhibitor UH15-38 protected models against influenza-induced inflammation and lung injury. Learn how it selectively blocks pathogenic necroptosis.
-
St. Jude survivorship portal brings researchers ‘one-click’ away from discovery
04/09/2024
Learn about the survivorship portal, a part of the St. Jude Cloud ecosystem, and find out how researchers can use the portal to make new discoveries.
-
Targeting vulnerability in B-cell development leads to novel drug combination for leukemia
04/08/2024
Discover how a vulnerability in treatment resistant B-cell acute lymphoblastic leukemia (B-ALL) was uncovered by single-cell analysis of developmental stage.
-
Renowned St. Jude clinician and researcher to receive coveted award at AACR annual meeting
04/04/2024
St. Jude researchers to present their science at AACR annual meeting.
-
Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes
03/28/2024
See how chemotherapy resistance in bilateral Wilms tumor implies stromal predominant with favorable outcomes if surgery follows rather than further chemo or biopsy
-
Researchers turn back the clock on cancer cells to offer new treatment paradigm
03/27/2024
Rhabdoid tumor cells were reverted from a cancerous state to normal. Discover how deletion of quality control protein DCAF5 may treat an undruggable cancer.
-
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer
03/19/2024
Explore how a T-cell receptor targeting an oncogenic fusion holds treatment promise in fibrolamellar carcinoma (FLC), a rare liver cancer with poor prognosis.
-
Scientists find core regulatory circuit controlling identity of aggressive leukemia
03/19/2024
Anaplastic large cell lymphoma is an aggressive form of cancer. Learn how a core regulatory circuit & STAT3 in ALCL may lead to new therapeutic opportunities.
-
Change in MYCN-driven cell state opens therapeutic window in high-risk neuroblastoma
03/19/2024
See how mesenchymal to adrenergic cell change mechanism in MYCN-linked neuroblastoma linked to high MYCN levels, driven by KDM4 induction.
-
Role in mitochondrial metabolism paints more complete picture of MCL-1 function
03/18/2024
See how anti-apoptosis oncoprotein MCL-1 also functions in fatty acid metabolism by binding ACSL1 explaining cardiac toxicity in clinical trials
-
Rare inflammatory disease responds best to double inhibition
03/06/2024
Ruxolitinib treats hemophagocytic lymphohistiocytosis (HLH) models better than JAK1 or 2 single inhibitors. Discover its promise in an ongoing clinical trial.
-
St. Jude taps health care start-up veteran as first Senior Vice President of Tech Commercialization
02/20/2024
New VP will work with St. Jude researchers to commercialize discoveries made at St. Jude to benefit more patients.
-
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
02/12/2024
Learn why bispecific chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) improved treatment, confirmed by artificial intelligence.
-
Sara Federico, MD, named director of the Solid Tumor Division at St. Jude Children’s Research Hospital
02/07/2024
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
-
Inaugural class of Damon Runyon– St. Jude Pediatric Cancer Research Fellows announced
02/01/2024
This initiative supports early-career scientists studying pediatric cancer, addressing a funding gap between pediatric and adult cancer research.
-
St. Jude Children’s Research Hospital adds $13 million project to Research Collaboratives Program
01/18/2024
Created as part of the 2022-2027 Strategic Plan, the St. Jude Research Collaboratives program is part of an overall effort by the institution to fund collaborative research addressing complex scientific problems with transformative potential for the diseases treated at St. Jude.
-
Molecular ‘super-glue’ shows promise of cancer drug discovery platform
01/16/2024
Learn how St. Jude created a molecular super-glue to target cancer-related protein casein kinase 1 alpha (CK1α) & how the platform may lead to new treatments.
-
St. Jude Home Care, LLC is first U.S. pediatric home health agency to earn new category of industry certification
01/16/2024
The mobile service was certified by CHAP in pediatrics and home health.
-
HOXA9 tracking reveals RBM5 dual function and therapeutic potential for acute myeloid leukemia
01/12/2024
See how St. Jude researchers use CRISPR-Cas9 to identify RBM5 as a key play in HOXA9-associated leukemia and how RBM5 was shown to have a duel function as splicing factor and transcription factor.
-
Two common biomarkers predict heart risk in asymptomatic childhood cancer survivors
01/11/2024
Find how global longitudinal strain (GLS) & N-terminal-pro-B-type natriuretic peptide (NT-proBNP) improved heart risk predictions in pediatric cancer survivors.
-
Updated genomic landscape for pediatric acute myeloid leukemia enables new treatment possibilities
01/11/2024
Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.
-
Acute pediatric critical illness definition enables global research
01/08/2024
Find how a new more inclusive consensus definition of acute pediatric critical illness will fuel research across the globe due to St. Jude-led collaboration.
-
A new approach can address antibiotic resistance to Mycobacterium abscessus
01/05/2024
Learn how St. Jude scientists developed a new form of spectinomycin, which overcomes efflux and thus antibiotic resistance in Mycobacterium abscessus.
-
Elusive cytonemes guide neural development, provide signaling ‘express route’
01/02/2024
Discover the first images of cytonemes during mammalian neural development, serving as express routes to establish morphogen gradients and tissue patterning.
